HomeCompareDASTF vs JNJ

DASTF vs JNJ: Dividend Comparison 2026

DASTF yields 1.61% · JNJ yields 2.14%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 DASTF wins by $3.14M in total portfolio value
10 years
DASTF
DASTF
● Live price
1.61%
Share price
$19.25
Annual div
$0.31
5Y div CAGR
85.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$3.17M
Annual income
$2,532,050.65
Full DASTF calculator →
JNJ
Johnson & Johnson
● Live price
2.14%
Share price
$242.49
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.5K
Annual income
$4,749.88
Full JNJ calculator →

Portfolio growth — DASTF vs JNJ

📍 DASTF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodDASTFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, DASTF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
DASTF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

DASTF
Annual income on $10K today (after 15% tax)
$136.88/yr
After 10yr DRIP, annual income (after tax)
$2,152,243.05/yr
JNJ
Annual income on $10K today (after 15% tax)
$182.28/yr
After 10yr DRIP, annual income (after tax)
$4,037.40/yr
At 15% tax rate, DASTF beats the other by $2,148,205.65/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of DASTF + JNJ for your $10,000?

DASTF: 50%JNJ: 50%
100% JNJ50/50100% DASTF
Portfolio after 10yr
$1.60M
Annual income
$1,268,400.26/yr
Blended yield
79.27%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

DASTF
Analyst Ratings
2
Hold
Consensus: Hold
Altman Z
3.1
Piotroski
7/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-5.7% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

DASTF buys
0
JNJ buys
0
No recent congressional trades found for DASTF or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricDASTFJNJ
Forward yield1.61%2.14%
Annual dividend / share$0.31$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR85.6%28%
Portfolio after 10y$3.17M$30.5K
Annual income after 10y$2,532,050.65$4,749.88
Total dividends collected$3.09M$15.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy

Year-by-year: DASTF vs JNJ ($10,000, DRIP)

YearDASTF PortfolioDASTF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$10,999$298.89$10,594$274.49+$405.00DASTF
2$12,339$570.23$11,294$360.69+$1.0KDASTF
3$14,312$1,109.63$12,133$476.91+$2.2KDASTF
4$17,547$2,232.57$13,156$635.42+$4.4KDASTF
5$23,523$4,747.72$14,432$854.61+$9.1KDASTF
6$36,209$11,040.01$16,056$1,162.76+$20.2KDASTF
7$68,222$29,477.86$18,175$1,604.53+$50.0KDASTF
8$169,334$96,336.87$21,009$2,252.68+$148.3KDASTF
9$595,958$414,770.28$24,911$3,229.73+$571.0KDASTF
10$3,169,726$2,532,050.65$30,458$4,749.88+$3.14MDASTF

DASTF vs JNJ: Complete Analysis 2026

DASTFStock

Dassault Systèmes SE provides software solutions and services worldwide. It offers SOLIDWORKS design software for 3D design, electrical and printed circuit board design, product data management, simulation, manufacturing, and technical communication; CATIA, an engineering and design software for product 3D computer-aided design; GEOVIA for modeling and simulating the earth; and BIOVIA that provides the scientific community with advanced biological, chemical, and materials experiences. The company also provides SIMULIA that delivers realistic simulation applications; DELMIA, which enables global industrial operations; 3DVIA that provides 3D space planning solutions; and ENOVIA that enables to plan and track the definition of success for customer. In addition, it offers Centric PLM, a product lifecycle management software solution; 3DEXCITE, a real-time 3D visualization software; NETVIBES, which enables organizations to gather, align, and enrich big data; 3DEXPERIENCE platform that provides organizations a holistic and real-time view of their business activities and ecosystem, as well as connecting people, ideas, data, and solutions together in a single environment; and MEDIDATA, a clinical research study software that provides evidences and insights to pharmaceutical, biotech, medical device, and diagnostic companies, as well as academic researchers. Further, the company provides consulting, deployment, outcome based, and training services. It primarily serves companies in the transportation and mobility; industrial equipment; aerospace and defense; high-tech; life sciences and healthcare; energy and materials; home and lifestyle; construction, cities, and territories; consumer packaged goods and retail; marine and offshore; and business services sectors through distributors and resellers. Dassault Systèmes SE was incorporated in 1981 and is headquartered in Vélizy-Villacoublay, France.

Full DASTF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this DASTF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

DASTF vs SCHDDASTF vs JEPIDASTF vs ODASTF vs KODASTF vs MAINDASTF vs ABBVDASTF vs MRKDASTF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.